Ensysce Biosciences Makes Strides in Opioid Overdose Protection with Successful FDA Meeting for PF614-MPAR.

In an unprecedented move towards improving opioid safety, Ensysce Biosciences Inc. recently announced a successful meeting with the U.S. Food and Drug Administration (FDA) regarding its next-generation opioid, PF614-MPAR. This pivotal development not only marks a significant milestone for Ensysce but could also have far-reaching implications for the entirety of the opioid industry. $Ensysce Biosciences(ENSC.US)$